Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COIN A: Continuous vs intermittent chemotherapy ± cetuximab in first-line metastatic colorectal cancer
2004-002951-16Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Medical Research Council. Primary endpoint: Overall Survival. Started Nov 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2004-002951-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002951-16.